Day: April 25, 2025

Invitation to Q1 2025 results presentation in Oslo on 5 May   BW Energy will release its first quarter 2025 results on Monday, 5 May at 07:30 CEST.   The Company will hold a presentation followed by Q&A at Hotel Continental in Oslo, Norway, on the same day at 09:30 CEST. The presentation will include an extended review of optimisation and development projects in Brazil. It will be hosted by CEO Carl K. Arnet, CFO Brice Morlot, CSO Thomas Young, CTO Jerome Bertheau and CCO Thomas Kolanski.  You can also follow the presentation via webcast with supporting slides, available on:  Viewer Registration • Q1 2025  For further information, please contact:  ir@bwenergy.no    About BW Energy:  BW Energy is a growth E&P company with a differentiated strategy targeting proven offshore oil and gas reservoirs through low risk phased developments....

The Supervisory Board of AS Ekspress Grupp approved the group’s audited annual report 2024 and submits it to the General Meeting of Shareholders for approval. The financial results for 2024 remain unchanged compared to the preliminary disclosure on 21st February 2025. In 2024, the consolidated audited sales revenue of AS Ekspress Grupp totalled EUR 76.2 million which increased by 4% compared to 2023. Group’s consolidated audited net profit for 2024 totalled EUR 3.3 million. Digital revenues increased by 9% year-over-year and the share of digital revenues was 86% of the group’s total revenue. AS Ekspress Grupp audited annual report for 2024 is published in accordance with the European Single Electronic Format (ESEF) requirements as an XHTML file and as a PDF file. The Group’s primary statements and notes to statements are labelled...

Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the influenza virus, from an infected person to household members by 32%1 CENTERSTONE is the first global phase III trial that demonstrates the benefit of an antiviral in reducing the spread of a respiratory virus1 Reducing the spread of infection within households could help limit transmission within institutions and communities, potentially easing the burden of both seasonal and pandemic influenza on healthcare systems2,3Basel, 25 April 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).1 The trial met its primary endpoint, showing a single, oral dose of Xofluza taken...

Rotterdam, The Netherlands (25 April 2025) – IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2025 results. HIGHLIGHTS• Gross profit up by 10% to EUR 325 million (+10% on a constant currency basis)• Operating EBITA up by 12% to EUR 142 million (+12% on a constant currency basis)• Free cash flow of EUR 102 million (first three months of 2024: EUR 106 million)• Cash earnings per share up by 10% to EUR 1.55 (first three months of 2024: EUR 1.41) Marcus Jordan, CEO: “After 26 years at IMCD, I am excited to take over the role of CEO and very much look forward to continuing the successful growth story of IMCD. We have had a good start to the year, with an increase in operating EBITA to EUR 142 million (+12%) and an...

The Supervisory Board of AS LHV Group, based on the authorisation granted by the General Meeting of shareholders held on 26 March 2025, approved the following terms for the acquisition of LHV Group’s own shares:The maximum volume of acquisition is up to 3.3 million shares within one year; The acquisition price per share must not exceed: (i) the average market price over the last 30 trading days by more than 50%, and (ii) the closing price on the previous trading day on Nasdaq Tallinn; The authorised agent for the transactions is AS LHV Pank, acting independently and on a market-based basis; All transactions, including shareholder-initiated block trades, will be executed on the regulated market Nasdaq Tallinn; The acquisition may commence on the date of this announcement; Summary data (daily volume and...

Press Release April 25, 2025 Signify delivers update on CEO succession process; CFO Željko Kosanović appointed interim CEO Eindhoven, The Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today delivered an update on the succession of CEO Eric Rondolat, who steps down after today’s Annual General Meeting of Shareholders (AGM). The Supervisory Board stated that it is on track to complete its review of internal and external candidates and expects to conclude the process next month. Željko Kosanović has been appointed as interim CEO of Signify in addition to continuing his role as CFO. “We are pleased that Željko Kosanović has agreed to serve as interim CEO. With his extensive experience and knowledge of the business, Željko is well suited to lead the company through this transition period,” said Gerard van de...

HIGHLIGHTSNet profit of $42.6 million and earnings per share of $0.56 for the first quarter 2025, compared to net income of $210.2 million and earnings per share of $2.74 for the fourth quarter 2024. On February 28, 2025, the sale of the four Mid-Sized Gas Carriers (“MGCs”) newbuilding contracts to subsidiaries of Exmar LPG B.V. (“Exmar”) was successfully completed. Avance Gas received reimbursement of $62.1 million of yard instalments paid by Avance Gas to the yard. The Company recorded a gain on sale of $34.2 million in relation to the sale for the first quarter. In April, 2025, the final milestone payment from Exmar of $34.2 million was received at steel cutting of the fourth and final MGC newbuilding bringing the total cash proceeds from Exmar to $96.3 million of which $62.1 million was received in March and $34.2 million was received...

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Repositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recovery Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2024 financial results for the period ended December 31, 2024 and provided a corporate...